Press Releases

June 29, 2009

New chronotherapy for Addison´s disease

Helsingborg June 29th 2009- DuoCort publishes data from its Phase I study for the rare and life threatening disease adrenal insufficiency. The release profile of DuoCort’s new form of treatment with once-a-day hydrocortisone dosing resembles the physiological secretion pattern. The data is published today in the European Journal of Endocrinology, a leading scientific journal for endocrinology.

June 12, 2009

Successful phase II/III trial of new therapy for Addison´s disease

Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.

Share this page

Subscribe

Read more about our Protection of your personal data.
No
Yes

Aqilion uses cookies in order to optimize your experience and use of our website as well as to be able to analyze the users’ usage of the website. Choose yourself if you would like to accept the cookies. Before you make your choice we encourage you to read our cookie policy. Do you accept our cookie policy?